Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05085548 · ClinicalTrials.gov registry record · Phase 1
ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
A Phase 1 study of Solid Tumor Malignancies and Advanced Pancreatic Cancer, sponsored by ProDa BioTech.
- Active
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT05085548: Active Phase 1 study of Solid Tumor Malignancies and Advanced Pancreatic Cancer, sponsored by ProDa BioTech.
NCT05085548 is a Phase 1 study of Solid Tumor Malignancies and Advanced Pancreatic Cancer that is active but no longer recruiting, run by ProDa BioTech. The registered enrollment target is 58 participants, below the 190-participant average among 11 other Solid Tumor Malignancies trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05085548, a Phase 1 study of Solid Tumor Malignancies and Advanced Pancreatic Cancer, is active but no longer recruiting, sponsored by ProDa BioTech.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is a first-in-human, Phase I study to assess the safety of ProAgio in participants with advanced solid tumor malignancies including pancreatic cancer.
Primary Outcome
Following completion of the dose escalation cohort, all available data relating to the pharmacokinetics, pharmacodynamics, efficacy and safety of ProAgio will be reviewed by the study team including the Principle Investigator, clinical pharmacology collaborators and the sponsor. A single ideal dose will then be selected for further investigation in the dose escalation cohort. This ideal dose may or may not be the same as the MTD.
Conditions Studied
Interventions
- DRUG ProAgio Dose Levels (DL) 1,2,3
- DRUG ProAgio Dose Levels (DL) 4,5,6
- DRUG ProAgio Dose Levels 4a,5a,6a
Study Locations (1)
Maryland
- National Cancer Institute - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2021-10-29 |
| Est. Completion | 2026-01 |
| Phase | Phase 1 |
What the registry record for NCT05085548 still lists
NCT05085548 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 190-participant average among 11 other Solid Tumor Malignancies trials with a reported enrollment target (69% lower).
The record links to 2 conditions, with Solid Tumor Malignancies appearing as the primary indexed condition, and to 3 interventions - of which ProAgio Dose Levels (DL) 1,2,3 is the first listed.
NCT05085548 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT05085548 about?
NCT05085548 is a clinical study titled "ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies". The study is a first-in-human, Phase I study to assess the safety of ProAgio in participants with advanced solid tumor malignancies including pancreatic cancer.
What is the current status of trial NCT05085548?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2021-10-29. Estimated completion is 2026-01.
What conditions does trial NCT05085548 study?
This clinical trial studies the following conditions: Solid Tumor Malignancies, Advanced Pancreatic Cancer.
What interventions are being tested in trial NCT05085548?
The interventions under investigation include: ProAgio Dose Levels (DL) 1,2,3 (DRUG), ProAgio Dose Levels (DL) 4,5,6 (DRUG), ProAgio Dose Levels 4a,5a,6a (DRUG).
Who is sponsoring clinical trial NCT05085548?
This trial is sponsored by ProDa BioTech, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05085548 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05085548's enrollment target sits among peer trials
58 11th of 11 higher than 1 of 11 other Solid Tumor Malignancies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor Malignancies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
RECRUITING · Phase 1
-
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI